JANICE L GABRILOVE, MD
Osteopathic Medicine in New York, NY
License number
New York 140741
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
1190 Avenue Guggenheim Pavill Mount Sinai Hospital-Ruttenberg Treatment Ctr, New York, NY 10029
Phone
(212) 241-6756
(212) 423-0522 (Fax)
(212) 987-3100
(212) 731-5210 (Fax)
(212) 423-0522 (Fax)
(212) 987-3100
(212) 731-5210 (Fax)
Personal information
See more information about JANICE L GABRILOVE at radaris.comName
Address
Phone
180 E End Ave APT 1A, New York, NY 10128
25 E 86Th St #5A, New York, NY 10028
New York, NY
180 End Ave, New York, NY 10128
180 End Ave, New York, NY 10128
Professional information
See more information about JANICE L GABRILOVE at trustoria.com
Human Pluripotent Hematopoietic Colony Stimulating Factor, Method Of Production And Use
Human Pluripotent Hematopoietic Colony Stimulating Factor, Method Of Production And Use
US Patent:
2005006, Mar 24, 2005
Filed:
Oct 5, 2004
Appl. No.:
10/958942
Inventors:
Karl Welte - New York NY, US
Erich Platzer - Erlangen, DE
Janice Gabrilove - New York NY, US
Roland Mertelsmann - Mainz, DE
Malcolm Moore - Larchmont NY, US
Erich Platzer - Erlangen, DE
Janice Gabrilove - New York NY, US
Roland Mertelsmann - Mainz, DE
Malcolm Moore - Larchmont NY, US
International Classification:
A61K038/19, C07H021/04, C07K014/535, C12P021/02
US Classification:
424085100, 530351000, 536023500, 435069500, 435320100, 435325000
Abstract:
Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5×10U/mg protein.
Process For Producing Arsenic Trioxide Formulations And Methods For Treating Cancer Using Arsenic Trioxide Or Melarsoprol
Process For Producing Arsenic Trioxide Formulations And Methods For Treating Cancer Using Arsenic Trioxide Or Melarsoprol
US Patent:
6884439, Apr 26, 2005
Filed:
Jan 16, 2004
Appl. No.:
10/759291
Inventors:
Pier Paolo Pandolfi - New York NY, US
Janice L. Gabrilove - New York NY, US
Janice L. Gabrilove - New York NY, US
Assignee:
Memorial Sloan-Kettering Cancer Center - New York NY
International Classification:
A61K033/36
US Classification:
424623
Abstract:
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Process For Producing Arsenic Trioxide Formulations And Methods For Treating Cancer Using Arsenic Trioxide Or Melarsoprol
Process For Producing Arsenic Trioxide Formulations And Methods For Treating Cancer Using Arsenic Trioxide Or Melarsoprol
US Patent:
2004014, Jul 29, 2004
Filed:
Jan 16, 2004
Appl. No.:
10/759293
Inventors:
Raymond Warrell - Westfield NJ, US
Pier Pandolfi - New York NY, US
Janice Gabrilove - New York NY, US
Pier Pandolfi - New York NY, US
Janice Gabrilove - New York NY, US
Assignee:
Memorial Sloan-Kettering Cancer Center - New York NY
International Classification:
A61K033/36
US Classification:
424/623000
Abstract:
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Process For Producing Arsenic Trioxide Formulations And Methods For Treating Cancer Using Arsenic Trioxide Or Melarsoprol
Process For Producing Arsenic Trioxide Formulations And Methods For Treating Cancer Using Arsenic Trioxide Or Melarsoprol
US Patent:
2004014, Jul 29, 2004
Filed:
Jan 16, 2004
Appl. No.:
10/759882
Inventors:
Raymond Warrell - Westfield NJ, US
Pier Pandolfi - New York NY, US
Janice Gabrilove - New York NY, US
Pier Pandolfi - New York NY, US
Janice Gabrilove - New York NY, US
Assignee:
Memorial Sloan-Kettering Cancer Center - New York NY
International Classification:
A61K033/36
US Classification:
424/623000
Abstract:
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Method Of Producing Human Pluripotent Hematopoietic Colony Stimulating Factor
Method Of Producing Human Pluripotent Hematopoietic Colony Stimulating Factor
US Patent:
5808008, Sep 15, 1998
Filed:
Mar 12, 1997
Appl. No.:
8/816159
Inventors:
Karl Welte - New York NY
Erich Platzer - Spardorf, DE
Janice L. Gabrilove - New York NY
Roland Mertelsmann - Mainz, DE
Malcolm A. S. Moore - Larchmont NY
Erich Platzer - Spardorf, DE
Janice L. Gabrilove - New York NY
Roland Mertelsmann - Mainz, DE
Malcolm A. S. Moore - Larchmont NY
Assignee:
Sloan-Kettering Institute of Cancer Research - New York NY
International Classification:
C07K 114, C07K 118, C07K 122, C07K 130
US Classification:
530412
Abstract:
Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1. 5. times. 10. sup. 8 U/mg protein.
Process For Producing Arsenic Trioxide Formulations And Methods For Treating Cancer Using Arsenic Trioxide Or Melarsoprol
Process For Producing Arsenic Trioxide Formulations And Methods For Treating Cancer Using Arsenic Trioxide Or Melarsoprol
US Patent:
6861076, Mar 1, 2005
Filed:
Jan 16, 2004
Appl. No.:
10/758994
Inventors:
Pier Paolo Pandolfi - New York NY, US
Janice L. Gabrilove - New York NY, US
Janice L. Gabrilove - New York NY, US
Assignee:
Memorial Sloan-Kettering Cancer Center - New York NY
International Classification:
A61K033/36
US Classification:
424623
Abstract:
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Process For Producing Arsenic Trioxide Formulations And Methods For Treating Cancer Using Arsenic Trioxide Or Melarsoprol
Process For Producing Arsenic Trioxide Formulations And Methods For Treating Cancer Using Arsenic Trioxide Or Melarsoprol
US Patent:
2004014, Jul 29, 2004
Filed:
Jan 16, 2004
Appl. No.:
10/758996
Inventors:
Raymond Warrell - Westfield NJ, US
Pier Pandolfi - New York NY, US
Janice Gabrilove - New York NY, US
Pier Pandolfi - New York NY, US
Janice Gabrilove - New York NY, US
Assignee:
Memorial Sloan-Kettering Cancer Center - New York NY
International Classification:
A61K033/36
US Classification:
424/623000
Abstract:
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Process For Producing Arsenic Trioxide Formulations And Methods For Treating Cancer Using Arsenic Trioxide Or Melarsoprol
Process For Producing Arsenic Trioxide Formulations And Methods For Treating Cancer Using Arsenic Trioxide Or Melarsoprol
US Patent:
2004014, Jul 29, 2004
Filed:
Jan 16, 2004
Appl. No.:
10/759726
Inventors:
Raymond Warrell - Westfield NJ, US
Pier Pandolfi - New York NY, US
Janice Gabrilove - New York NY, US
Pier Pandolfi - New York NY, US
Janice Gabrilove - New York NY, US
Assignee:
Memorial Sloan-Kettering Cancer Center - New York NY
International Classification:
A61K033/36
US Classification:
424/623000
Abstract:
The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.
Human Pluripotent Hematopoietic Colony Stimulating Factor And Cell Line Producing Same
Human Pluripotent Hematopoietic Colony Stimulating Factor And Cell Line Producing Same
US Patent:
6114166, Sep 5, 2000
Filed:
Dec 22, 1997
Appl. No.:
8/996051
Inventors:
Karl Welte - New York NY
Erich Platzer - Erlangen, DE
Janice L. Gabrilove - New York NY
Roland Mertelsmann - Mainz, DE
Malcolm A. S. Moore - Larchmont NY
Erich Platzer - Erlangen, DE
Janice L. Gabrilove - New York NY
Roland Mertelsmann - Mainz, DE
Malcolm A. S. Moore - Larchmont NY
Assignee:
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
C12N 508
US Classification:
435366
Abstract:
Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1. 5. times. 10. sup. 8 U/mg protein.
Stimulation, Production, Culturing And Transplantation Of Stem Cells By Fibroblast Growth Factors
Stimulation, Production, Culturing And Transplantation Of Stem Cells By Fibroblast Growth Factors
US Patent:
5817773, Oct 6, 1998
Filed:
Feb 23, 1996
Appl. No.:
8/605919
Inventors:
Elaine Lynette Wilson - New York NY
Janice Gabrilove - New York NY
Janice Gabrilove - New York NY
Assignee:
New York University - New York NY
Sloan-Kettering Institute for Cancer Research - New York NY
Sloan-Kettering Institute for Cancer Research - New York NY
International Classification:
A61K 3818
US Classification:
530399
Abstract:
Fibroblast growth factors are used in vivo, in situ and in vitro to stimulate stem cells, hemopoiesis, the immune system, transplant donor cells, culture and/or engraftment, wherein the use of fibroblast growth factors is disclosed for the stimulation of stem cells or hemopoietic cells, supporting cells and their progeny, in vitro, in situ and in vivo, as well as corresponding engrafting sites in vivo.